Compare VanEck Junior Gold Miners (GDXJ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Recursion Pharmaceuticals Inc — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: VanEck Junior Gold Miners is far larger — about 3.8× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 3,212,198). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GDXJ | RXRX | |
|---|---|---|
Market Cap | $8.22B | $2.14B |
Volume | 3,212,198 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $6.79 |
52-Week Low | $87.56 | $2.84 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% today. The technical outlook is bearish with moving averages signaling a downtrend, while oscillators are neutral. Recent news highlights multiple junior gold mining companies being added to the ETF's index, potentially broadening its investor base. Key support is at $110, with resistance at $112.
The outlook remains cautious due to the bearish technical structure and reliance on gold price volatility. Opportunities exist if gold rallies, but risks include sector-specific volatility and macroeconomic factors affecting mining stocks. Investor sentiment is mixed, with institutional activity showing some selling pressure.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
